The phrase "a dose formulation" is correct and usable in written English.
It can be used in contexts related to pharmaceuticals, medicine, or any field discussing the preparation of a specific dosage of a drug or substance.
Example: "The study focused on the effectiveness of a dose formulation designed to improve patient compliance."
Alternatives: "a dosage form" or "a medication formulation."
When a dose formulation sample analysis result does not meet the stated acceptance criteria, the typical first reaction is to assume an error was made by the analyzing laboratory.
That is, there may be a dose, formulation, and delivery strategy of surfactant that could be effective in patients in ARDS, potentially when combined with other therapies such as lung protective ventilation [ 6], high-frequency ventilation [ 32], prone positioning [ 33], or extracorporeal membrane oxygenation [ 34].
Discontinuation was defined as stopping any antiretroviral drug for at least 2 weeks or switching (changing one or more drugs) to another regimen; the only exception was a substitution of lamivudine with emtricitabine or vice-versa, because it could simply reflect a shift to a fixed dose formulation of tenofovir-emtricitabine, abacavir-lamivudine or zidovudine-lamivudine.
The five volunteers who received the low dose of AMA-1/AS01B were not randomized nor blinded to the vaccine administered in order to conduct the appropriate safety evaluation of this vaccine formulation prior to proceeding with a higher dose formulation.
· Artequin Paediatric : a fixed dose formulation of granules containing: AS 50 mg and MQ 125 mg per dose.
More recently, a higher dose formulation (40 mg) administered three times per week has been approved in the US for use in patients with RRMS [ 41].
This product is a sweet-tasting, dispersible pediatric dose formulation of a malaria drug combination treatment used widely for adults.
This analytical method was applied in a relative bioavailability study in order to compare a test chlorpromazine 100 mg simple dose formulation versus a reference in 57 volunteers of both sexes.
Presently, no regulatory authority has a guidance document for nonclinical dose formulation analysis out of specification (NCDFA-OOS) investigations.
Lack of exclusive use of any particular dose category means that we cannot know whether any associations between death and oestrogen dosage are due to the effects of the preparation used most recently before death or lingering effects from a previously used (usually higher dose) formulation.
However, subgroup analyses did not identify an optimal supplementation strategy (ie, dose, formulation and frequency), and large trials comparing active interventions could inform clinical guidelines.
